Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients

[1]  P. Vanhems,et al.  Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. , 2011, Medical mycology.

[2]  Lennart Sjöberg,et al.  Ahlstrand E , Persson L , Tidefelt U , Söderquist B. Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy. Eur J Clin Microbiol Infect Dis , 2011 .

[3]  L. Pagano,et al.  Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). , 2010, The Journal of antimicrobial chemotherapy.

[4]  Giuseppe Leone,et al.  Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.

[5]  D. Kontoyiannis,et al.  Fungal infections in leukemia patients: how do we prevent and treat them? , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[7]  J. Ito,et al.  Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Zaragoza,et al.  Critical overview of clinical guidelines relating to invasive fungal infections. , 2008, International journal of antimicrobial agents.

[9]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[12]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[13]  B. D. de Pauw,et al.  Prophylaxis and aspergillosis--has the principle been proven? , 2007, The New England journal of medicine.

[14]  C. Viscoli,et al.  Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin , 2006, British journal of haematology.

[15]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[17]  E. Anaissie,et al.  Prevention of fungal infections in the immunocompromised host. , 2003, Current opinion in investigational drugs.

[18]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[19]  J. Bergerat,et al.  Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[21]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  F. Garfield,et al.  CLINICAL JUDGMENT AND CLINICAL PRACTICE GUIDELINES , 2000, International Journal of Technology Assessment in Health Care.

[23]  F. Lampe,et al.  Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  H. Prentice,et al.  Towards a targeted, risk‐based, antifungal strategy in neutropenic patients , 2000, British journal of haematology.

[25]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[26]  A. Kornblith,et al.  Cancer and Leukemia Group B (CALGB). , 1996, Journal of the National Cancer Institute. Monographs.

[27]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Frelick.  Cancer and leukemia group B (CALGB). , 1979, Delaware medical journal.

[29]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.